In the last trading session, 6.01 million shares of the Cue Biopharma Inc (NASDAQ:CUE) were traded, and its beta was 1.94. Most recently the company’s share price was $1.16, and it changed around $0.34 or 41.60% from the last close, which brings the market valuation of the company to $69.84M. CUE currently trades at a discount to its 52-week high of $3.25, offering almost -180.17% off that amount. The share price’s 52-week low was $0.45, which indicates that the current value has risen by an impressive 61.21% since then. We note from Cue Biopharma Inc’s average daily trading volume that its 10-day average is 1.37 million shares, with the 3-month average coming to 431.80K.
Cue Biopharma Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended CUE as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Cue Biopharma Inc is expected to report earnings per share of -0.19 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cue Biopharma Inc (NASDAQ:CUE) trade information
Instantly CUE has showed a green trend with a performance of 41.60% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.2300 on recent trading dayincreased the stock’s daily price by 5.69%. The company’s shares are currently down -56.06% year-to-date, but still up 70.74% over the last five days. On the other hand, Cue Biopharma Inc (NASDAQ:CUE) is 84.13% up in the 30-day period. We can see from the shorts that 3.56 million shares have been sold at a short interest cover period of 16.24 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 80.67% from its current value. Analyst projections state that CUE is forecast to be at a low of $2 and a high of $7.
Cue Biopharma Inc (CUE) estimates and forecasts
Cue Biopharma Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -37.30 percent over the past six months and at a 23.42% annual growth rate that is well above the industry average of 17.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 20.80% in revenue this quarter, and will report an increase of 41.40% in the next quarter. The year-over-year growth rate is expected to be 102.70%, up from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 1.52M in revenue for the current quarter. 4 analysts expect Cue Biopharma Inc to make 5.23M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.13M and 1.82M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 34.50%. Forecasts for the next quarter put sales growth at 187.20%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 10.55%.
CUE Dividends
Cue Biopharma Inc’s next quarterly earnings report is expected to be released in November.
Cue Biopharma Inc (NASDAQ:CUE)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.55% of Cue Biopharma Inc shares, and 23.06% of them are in the hands of institutional investors. The stock currently has a share float of 23.19%. Cue Biopharma Inc stock is held by 96.0 institutions, with BLEICHROEDER LP being the largest institutional investor. By 2024-06-30, it held 5.7849% of the shares, which is about 2.86 million shares worth $3.55 million.
SLATE PATH CAPITAL LP, with 4.8567% or 2.4 million shares worth $2.98 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
